文献速递血栓与止血

My Life, Our Future 计划中 3000 例血友病患者基因分析的新方法与结果

Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative.
PubMed 文献 · Blood Adv · 2017-05-18

My Life, Our Future(MLOF)项目在美国 69 家血友病治疗中心纳入首批 3000 例血友病患者,采用集中下一代测序(NGS)同步检测常见 F8 基因倒位与 F8、F9 基因序列,并用标准方法确认。血友病 A 中 98.1%(2357/2401)、血友病 B 中 99.3%(595/599)检出可临床报告的 DNA 变异,共发现 924 种独特变异,其中 285 种为新变异。

要点

  • NGS 同步检测 F8 倒位与 F8/F9 序列,血友病 A 可报告变异检出率 98.1%(2357/2401),血友病 B 为 99.3%(595/599)。
  • 共发现 924 种独特变异,285 种为新变异;新变异约占所发现变异的 30%,且在整个项目期间持续检出。
  • 36 例患者(10 例女性)检出超过 1 种可报告变异;NGS 还检出 11 种既往报告于血友病但不致病的不相关变异。

核心结论

  • MLOF 项目对 F8 和 F9 基因的变异注释做出了显著贡献,未来研究者可获取 MLOF 数据和样本库样本用于研究以加深对血友病的理解。

研究设计与样本

  • MLOF 是合作项目,在美国血友病治疗中心纳入患者,集中采用 NGS 同步检测常见 F8 基因倒位与 F8、F9 基因序列,并用标准基因分型方法确认。
  • 69 家血友病治疗中心在不到 3 年内纳入首批 3000 例患者。

主要发现

  • 血友病 A 患者中 98.1%(2357/2401)检出可临床报告的 DNA 变异,血友病 B 患者中 99.3%(595/599)检出。
  • 共发现 924 种独特变异,其中 285 种为新变异。
  • 预测的基因破坏性变异在重度疾病中常见,错义变异在轻度至中度疾病中占主导。
  • 新 DNA 变异约占所发现变异的 30%,且在整个项目期间持续检出,提示可能仍有额外变异未被发现。
  • NGS 方法在 36 例患者(10 例女性)中检出超过 1 种可报告变异;还检出不太可能致病的不相关变异,包括 11 种既往报告于血友病的变异。

关键数值与推荐

  • 血友病 A 可报告变异检出率 98.1%(2357/2401)。
  • 血友病 B 可报告变异检出率 99.3%(595/599)。
  • 独特变异 924 种,其中新变异 285 种。
  • 超过 1 种可报告变异的患者 36 例,其中女性 10 例。
  • 不相关的不致病变异包括 11 种既往报告于血友病的变异。

临床怎么用

  • 作者认为,尽管这些基因被认为保守,研究结果支持在解读新变异时保持谨慎。
  • 原文未据此给出临床推荐。

局限性

  • 新 DNA 变异约占所发现变异的 30% 且持续检出,提示可能仍有额外变异未被发现。
  • 作者认为这些基因虽被认为保守,但研究结果支持在解读新变异时保持谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A and B are rare, X-linked bleeding disorders. My Life, Our Future (MLOF) is a collaborative project established to genotype and study hemophilia. Patients were enrolled at US hemophilia treatment centers (HTCs). Genotyping was performed centrally using next-generation sequencing (NGS) with an approach that detected common F8 gene inversions simultaneously with F8 and F9 gene sequencing followed by confirmation using standard genotyping methods. Sixty-nine HTCs enrolled the first 3000 patients in under 3 years. Clinically reportable DNA variants were detected in 98.1% (2357/2401) of hemophilia A and 99.3% (595/599) of hemophilia B patients. Of the 924 unique variants found, 285 were novel. Predicted gene-disrupting variants were common in severe disease; missense variants predominated in mild-moderate disease. Novel DNA variants accounted for ∼30% of variants found and were detected continuously throughout the project, indicating that additional variation likely remains undiscovered. The NGS approach detected >1 reportable variants in 36 patients (10 females), a finding with potential clinical implications. NGS also detected incidental variants unlikely to cause disease, including 11 variants previously reported in hemophilia. Although these genes are thought to be conserved, our findings support caution in interpretation of new variants. In summary, MLOF has contributed significantly toward variant annotation in the F8 and F9 genes. In the near future, investigators will be able to access MLOF data and repository samples for research to advance our understanding of hemophilia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Johnsen JM, Fletcher SN, Huston H, et al. Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Adv. 2017. PMID: 29296726. doi:10.1182/bloodadvances.2016002923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。